



FINANCIAL TEAR SHEET

CORPORATE PROFILE

We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.

STOCK MARKET DATA

ERYP.PA (Common Stock)

Exchange	Paris (Euro)
Price	€15.71
Change (%)	▲ 0.21 (1.35%)
Volume	49,619
52 Week Low	€15.27
Market Cap	€135,356,044
Rolling EPS	-2.95
PE Ratio	0

Shares Outstanding 8,732,648

Data as of 06/20/18 5:35 p.m. ET

ERYP (Common Stock)

Exchange	NASDAQ GS (US Dollar)
Price	\$18.19
Change (%)	▲ 0.63 (3.59%)
Volume	1,621
52 Week Low	\$17.50
Market Cap	\$
Rolling EPS	0.00
PE Ratio	0

Shares Outstanding

Data as of 06/20/18 10:51 a.m. ET

STOCK MARKET DATA



Data provided by Nasdaq. Minimum 15 minutes delayed.

RECENT NEWS & EVENTS

20-Jun-2018

ERYTECH to Present at JMP Securities Life Science Conference

15-Jun-2018

ERYTECH to Present Preclinical and Clinical Data on Use of Eryaspase in ALL and AML at EHA 2018

07-Jun-2018

Erytech Pharma S.A. : General Meeting to be held on June 28, 2018 and Availability of Related Materials

Date

Title

06/28/18 10:00 a.m. CET

General Meeting of Shareholders
Location Lyon

09/18/18 2:30 p.m. CET

Erytech Pharma Second Quarter 2018 Conference Call and Webcast

11/13/18 2:30 p.m. CET

Erytech Pharma Third Quarter 2018 Conference Call and Webcast

SEC FILINGS

Filing Date

Form

06/15/18

6-K

06/07/18

6-K

06/04/18

6-K

05/23/18

20-F/A

CORPORATE GOVERNANCE

Gil Beyen, MBA

Chairman and Chief Executive Officer

Eric Soyer, MBA

Chief Financial Officer & Chief Operating Officer

Yann Godfrin, PhD

Chief Scientific Officer

Iman El-Hariry, MD, PhD

Chief Medical Officer

Jérôme

Bailly, Pharm.D.

Director of Pharmaceutical

Operations and Qualified Person